Non-surgical treatments for heart and artery disease

Dr. Weeks’ Comment: I earned my credential as an ACAM certified IV EDTA  chelating doctor 23 years ago and have seen clinical miracle after miracle using this safe and effective and cost-effective (i.e. “centisble”) treatment which, like all medical innovations has passed through Arthur Schopenhauer’s Three Phases of Truth: “All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident.”  

Chelation therapy is now attaining the self-evident stage, but not before many brilliant, courageous and honorable doctors were harassed out of practice by state medical boards. Over the years, clinical studies supported chelation therapy and then peer-reviewed studies were added to the argument. As  science started to clarify the benefits of chelation, a break through happened in 2013: the Trial to Assess Chelation Therapy (TACT) trial shocked conventional medical doctors  by scientifically asserting incontrovertible benefits including:

• Patients with prior heart attacks enrolled in a clinical trial of a weekly chelation infusion regiment that included disodium EDTA and vitamin C had fewer cardiovascular disease complications than those who received placebo infusions.

• Chelation therapy removes heavy metals like lead and iron from the body. Disodium EDTA, the agent used in the study, does not have an FDA indication.

• Investigators caution that the results need to be reproduced and understood before consideration of clinical application… “

Now, a new peer-reviewed scientific article (see below) demonstrates the benefits of EDTA therapy using even more sensitive and clinically significant measurements: pulse wave velocity (PWV), central blood pressure (SBPao) and endothelial function (Aix).

So ask your doctor about whether he or she recommends chelation therapy and when the eyes roll, ask him or her if they are interested in new scientific findings which support non-surgical interventions and give him a print out of this post.   

For those who don’t like or can’t afford IV EDTA chelation treatments, an oral agent DrDetox is an excellent substitute therapy.  And for those already receiving IV EDTA chelation treatments, DrDetox is a powerful and thorough adjunctive therapy which chelating doctors are offering patients across America.  

“…The results of this study indicate that a course of treatment with Magnesium-EDTA chelation therapy significantly lowers cardiovascular risks…”No

 

Scientific Research – An Academic Publisher

Health, Vol.6 No.21, December 2014

http://www.scirp.org/Journal/PaperInformation.aspx?PaperID=52501

 

The Effects of Magnesium-EDTA Chelation Therapy on Arterial Stiffness

 

Authors

  1. J. Van der Schaar(1), R. Th. B. Pahlplatz(2), E. Blaurock-Busch(3)

 

Affiliations

1 International Board of Clinical Metal Toxicology, Leende, The Netherlands.

2 International Biomedical Centre, Leende, The Netherlands.

3 Micro Trace Minerals Laboratory, Hersbruck, Germany.

 

ABSTRACT

Traditional risk factors for cardiovascular disease can only assess risks for groups of people. New parameters of arterial stiffness are more reliable for predicting cardiovascular outcomes for individuals with and without a cardiovascular history.

 

The objective of this study was to assess the effects of Magnesium-EDTA chelation therapy using new methods and parameters such as pulse wave velocity (PWV), central blood pressure (SBPao) and endothelial function (Aix).

 

We followed 43 patients with an abnormal PWV and SBPao, setting them up in two groups. The 21 patients in Group A had already been diagnosed with cardiovascular disease. The other 22 patients in Group B also showed abnormal PWV, SBPao and Aix, but showed no cardiovascular symptoms. Each patient in Groups A and B received one Mg-EDTA treatment per week.

 

The total treatment plan consisted of 25 Mg-EDTA chelation treatments according to the standard protocol of IBCMT. After 25 Mg-EDTA chelation sessions, PWV and SBPao improved significantly in all patients of Groups A and B. In addition, Aix improved significantly in these patients, but remained abnormal. Group C included 18 asymptomatic patients with normal PWV or SBPao. Aix was abnormal in this group, but to a much lesser extent than Groups A and B. The 18 asymptomatic patients of Group C did not receive Mg-EDTA treatment. Observation showed no significant changes in all three parameters of arterial stiffness.

 

The results of this study indicate that a course of treatment with Magnesium-EDTA chelation therapy significantly lowers cardiovascular risks.

We conclude that Mg-EDTA chelation therapy improves PWV as an indicator of arterial stiffness, SBPao (central blood pressure) as an indicator of aortic elasticity and Aix (augmented aortic index) as an indicator of endothelial functioning.

These improvements in PWV, SBPao and Aix demonstrate that atherosclerosis is a dynamic and (partially) reversible process.

 

References

[1]       Lamas, G.A., et al. (2013) Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients with Previous Myocardial Infarction: The TACT Randomized Trial. JAMA, 309, 1241-1250.

http://dx.doi.org/10.1001/jama.2013.2107

 

[2]       The International Board of Clinical Metal Toxicology (IBCMT.com).

 

[3]       Chappell, L.T., et al. (2000) Brachial Artery Stiffness Testing as an Outcomes Measurement for EDTA-Treated Patients with Vascular Disease. Clinical Practice of Alternative Medicine, 1, 225-228.

 

[4]       Vlachopoulos, C., et al. (2012) Progress towards Identifying Biomarkers of Vascular Aging for Total Cardiovascular Risk Prediction. Journal of Hypertension, 30, S19-S26.

http://dx.doi.org/10.1097/HJH.0b013e328353e534

 

[5]       Liu, C.S., Li, C.I., Shih, C.M., Lin, W.Y., Lin, C.H., Lai, S.W., Li, T.C. and Lin, C.C. (2011) Arterial Stiffness Measured as Pulse Wave Velocity Is Highly Correlated with Coronaryatherosclerosis in Asymptomatic Patients. Journal of Atherosclerosis and Thrombosis, 18, 652-658.

http://dx.doi.org/10.5551/jat.7021

 

[6]       Turin, T.C., Kita, Y., Rumana, N., Takashima, N., Kadota, A., Matsui, K., Sugihara, H., Morita, Y., Nakamura, Y., Miura, K. and Ueshima, H. (2010) Brachial-Ankle Pulse Wave Velocity Predicts All-Cause Mortality in the General Population: Findings from the Takashima Study. Hypertension Research, 33, 922-925.

http://dx.doi.org/10.1038/hr.2010.103

 

[7]       Vlachopoulos, C., Aznaouridis, K. and Stefanadis, C. (2010) Prediction of Cardiovascular Events and All-Cause Mortality with Arterial Stiffness: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 55, 1318-1327.

http://dx.doi.org/10.1016/j.jacc.2009.10.061

 

[8]       Roman, M.J., Devereux, R.B., Kizer, J.R., Lee, E.T., Galloway, J.M., Ali, T., Umans, J.G. and Howard, B.V. (2007) Central Pressure More Strongly Relates to Vascular Disease and Outcome than Does Brachial Pressure: The Strong Heart Study. Hypertension, 50, 197-203.

http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.089078

 

[9]       Orlova, I.A., Kuz’mina, A.E., Barinova, I.V., Iarovaia, E.B. and Ageev, F.T. (2009) Assessment of Major Artery Stiffness: New Perspectives of Non-Invasive Diagnosis of Coronary Atherosclerosis. Terapevticheskii Arkhiv, 81, 8-13.

 

[10]     Verma, et al. (2002) Fundamentals of Endothelial Function, Interventions to Improve Endothelial Function. Circulation, 105, 546-549.

http://dx.doi.org/10.1161/hc0502.104540

 

[11]     Tellez-Plaza, M., Jones, M.R., Dominguez-Lucas, A., Guallar, E. and Navas-Acien, A. (2013) Cadmium Exposure and Clinical Cardiovascular Disease: A Systematic Review. Current Atherosclerosis Reports, 15, 356.

http://dx.doi.org/10.1007/s11883-013-0356-2

 

Page Three

 

[12]     Horváth, I.G., Németh, A., Lenkey, Z., Alessandri, N., Tufano, F., Kis, P., Gaszner, B. and Cziráki, A. (2010) Invasive Validation of a New Oscillometric Device (Arteriograph) for Measuring Augmentation Index, Centralblood Pressure and Aortic Pulse Wave Velocity. Journal of Hypertension, 28, 2068-2075.

http://dx.doi.org/10.1097/HJH.0b013e32833c8a1a

 

[13]     Roman, M.J., Devereux, R.B., Kizer, J.R., Lee, E.T., Galloway, J.M., Ali, T., Umans, J.G. and Howard, B.V. (2007) Central Pressure More Strongly Relates to Vascular Disease and Outcome than Does Brachial Pressure: The Strong Heart Study. Hypertension, 50, 197-203.

http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.089078

 

Filename: 2014-12-23-IBCMT-EffectsOfMagnesiumEDTAChelationTherapyOnArterialStiffness.doc

 

 

 

Share This Post

Dr. Weeks’ Comment: I earned my credential as an ACAM certified IV EDTA  chelating doctor 23 years ago and have seen clinical miracle after miracle using this safe and effective and cost-effective (i.e. “centisble”) treatment which, like all medical innovations has passed through Arthur Schopenhauer’s Three Phases of Truth: “All truth passes through three stages.…
&source=WeeksMD">